Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 3/20 | 0.43 |
| ▸ | HTR3A | P46098 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5364893 | 0.90 | HTR6 (0.65) | HTR6MAPTHTR1AADRB1NPSR1 | |
| SCHEMBL5366734 | 0.88 | HTR6 (0.64) | HTR6SMN1; SMN2HTR1AKMT2AADRB1 | |
| SCHEMBL5357019 | 0.88 | HTR6 (0.64) | HTR6LMNAMAPTSMN1; SMN2KMT2A | |
| SCHEMBL5366505 | 0.88 | HTR6 (0.74) | HTR6LMNAMAPTHTR1AKMT2A | |
| SCHEMBL5361814 | 0.88 | HTR6 (0.61) | HTR6MAPTSMN1; SMN2HTR1AHTR3A | |
| SCHEMBL5363785 | 0.87 | HTR6 (0.62) | HTR6MAPTHTR1AADRB1 | |
| SCHEMBL5360234 | 0.87 | HTR6 (0.83) | HTR6LMNAMAPTSMN1; SMN2HTR3A | |
| SCHEMBL8263965 | 0.84 | HTR6 (0.56) | HTR6HTR1AADRB1 | |
| SCHEMBL5361156 | 0.84 | HTR6 (0.68) | HTR6LMNAHTR1AHTR3AADRB1 | |
| SCHEMBL5366499 | 0.83 | HTR6 (0.58) | HTR6LMNAMAPTSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7229984-B2 | Dibenzoxazepinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-06-12 | — | — | US | claimed |
| US-20060154914-A1 | Dibenzoxazepinone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-07-13 | — | — | US | claimed |
| WO-2006061126-A2 | DIBENZOXAZEPINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-15 | — | — | WO | claimed |
| US-7229984-B2 | Dibenzoxazepinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-06-12 | — | — | US | disclosed |
| US-7229984-B2 | Dibenzoxazepinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-06-12 | — | — | US | disclosed |
| US-7229984-B2 | Dibenzoxazepinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-06-12 | — | — | US | disclosed |
| US-20060154914-A1 | Dibenzoxazepinone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-07-13 | — | — | US | disclosed |
| WO-2006061126-A2 | DIBENZOXAZEPINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154914-A1 | Dibenzoxazepinone derivatives and uses thereof | HTR6, BDKRB1, HTR7 | HTR6 1/4885LMNA 1520/4885MAPT 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.